Skip to content

Learning MRI and Histology Image Mappings for Cancer Diagnosis and Prognosis.

Learning MRI and Histology Image Mappings for Cancer Diagnosis and Prognosis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04792138
Acronym
Histo-MRI
Enrollment
300
Registered
2021-03-10
Start date
2020-10-23
Completion date
2023-10-31
Last updated
2021-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer, Prostate Neoplasm

Brief summary

Multiparametric magnetic resonance imaging (mpMRI) is now widely used to risk stratify men with a suspicion of prostate cancer and identify suspicious regions for biopsy. Advanced MRI techniques have emerged which seek to improve this characterisation and could predict biopsy results non-invasively before men undergo biopsy. Before these techniques are translated clinically, robust histological and clinical validation is required. This study aims to clinically validate advanced MRI techniques in a cohort of men suspected with prostate cancer. Histological analysis of men undergoing biopsy, +/- prostatectomy will be used for biological validation of VERDICT; Vascular and Extracellular Restricted Diffusion for Cytometry in Tumours and Luminal Water imaging (LWI). In particular, prostatectomy specimens will be processed using 3-D printed patient-specific moulds to allow for accurate MRI and histology mapping.

Interventions

DIAGNOSTIC_TESTVERDICT MRI

Advanced Diffusion Model

DIAGNOSTIC_TESTLuminal Index Imaging

Advanced T2 mapping

Sponsors

University College, London
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Men aged 18-90 with a clinical suspicion of prostate cancer * No contraindication to MRI

Exclusion criteria

* Men unable to have a MRI scan, or in whom artefact would reduce quality of MRI * Men unable to given informed consent * Previous treatment (prostatectomy, radiotherapy, brachytherapy) of prostate cancer * Ongoing hormonal treatment for prostate cancer

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic accuracy of VERDICT MRI2 yearsQuantitative assessment of VERDICT MRI reduces false positives by 10% compared to standard MRI alone
Diagnostic accuracy of Luminal Water Imaging (LWI)2 yearsQuantitative assessment of LWI reduces false positives by 10% compared to standard MRI alone

Secondary

MeasureTime frame
The proportions of true positives with index tests is the same as mpMRI.2 years

Other

MeasureTime frameDescription
Machine learning algorithms can predict histology from MRI.3 yearsNumber of correct predictions of gleason grade in men who undergo biopsy or prostatectomy.

Countries

United Kingdom

Contacts

Primary ContactJoey Clemente
j.clemente@nhs.net07886178028

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 11, 2026